Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results.
Quarterly Results
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Earnings per share rose 143.75% over the past year to $0.07, which beat the estimate of ($0.11).
Revenue of $501,693,000 higher by 16.81% year over year, which beat the estimate of $448,790,000.
Looking Ahead
Biomarin Pharmaceutical hasn't issued any earnings guidance for the time being.
The upcoming fiscal year's revenue expected to be between $1,790,000,000 and $1,880,000,000.
Conference Call Details
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Date: Jul 28, 2021
Time: 04:30 PM
ET Webcast URL: https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=F1263B20-BE46-4ECA-876D-F6FFD8F51EF3&Referrer=https%3A%2F%2Finvestors.biomarin.com%2F
Technicals
Company's 52-week high was at $124.90
Company's 52-week low was at $71.35
Price action over last quarter: Up 1.04%
Company Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin has a hemophilia A gene therapy and a treatment for achondroplasia in late-stage clinical trials.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.